Glucotrack Aims for FDA IDE Submission in Q2 2026 After Key Clinical Milestones — GlucoTrack, Inc.

Event summary

Glucotrack completed its first-in-human study in Brazil with a Mean Absolute Relative Difference (MARD) of 7.7% and no serious adverse events.
The company initiated a feasibility clinical trial in Australia in July 2025, providing protocol and product learnings for future studies.
Glucotrack secured three critical patents in October and November 2025 related to its CBGM platform.
The company plans to file an Investigational Device Exemption (IDE) with the FDA in early Q2 2026, aiming to initiate a U.S. clinical trial in the second half of 2026.

The big picture

Glucotrack's progress in clinical trials and patent acquisitions positions it as a contender in the rapidly growing continuous glucose monitoring (CGM) market. The company's focus on a fully implantable solution addresses unmet needs for patients with diabetes, potentially disrupting the current landscape dominated by subcutaneous sensors. Success hinges on navigating regulatory hurdles and securing reimbursement pathways in the U.S.

What we're watching

Regulatory Approval: The pace at which the FDA reviews Glucotrack's IDE submission will determine the timeline for initiating U.S. clinical trials.
Market Adoption: Whether Glucotrack can sustain interest from patients and healthcare providers pending FDA approval will be crucial for its commercial prospects.
Competitive Positioning: How Glucotrack's fully implantable CBGM technology differentiates itself against established players like Dexcom and Abbott will shape its market strategy.